Epoxyeicosatrienoic acids and soluble epoxide hydrolase

Potential therapeutic targets for inflammation and its induced carcinogenesis

Stephanie Norwood, Jie Liao, Bruce D. Hammock, Guang Yu Yang

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Chronic inflammation is an important factor contributing to human carcinoma, and non-steroidal antiinflammatory drugs (NSAIDs) have been shown to have a preventive effect in the development of various types of carcinoma. However, NSAIDs also have adverse side effects including increased cardiovascular events, making them less than ideal for routine chemoprevention. Soluble epoxide hydrolase (sEH) is an enzyme that converts endogenous anti-inflammatory compounds, the epoxyeicosatrienoic acids (EETs), to the less anti-inflammatory dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH, by a highly selective and potent sEH inhibitor (sEHI), increases EETs leading to decreased inflammation. In our studies, administration of a sEHI in mouse colitis models led to decreased ulcer incidence and number of ulcers compared to controls, with no adverse side effects seen. In human tissue, sEH showed an increase in expression, as seen immunohistochemically, in ulcerative colitis (UC), UC-induced dysplasia, and UCinduced carcinoma. Thus, inhibition of sEH may be a novel biomarker and potential therapeutic target in inflammation and inflammation-induced carcinoma.

Original languageEnglish (US)
Pages (from-to)447-457
Number of pages11
JournalAmerican Journal of Translational Research
Volume2
Issue number4
StatePublished - 2010

Fingerprint

Epoxide Hydrolases
Carcinogenesis
Inflammation
Anti-Inflammatory Agents
Acids
Carcinoma
Ulcerative Colitis
Ulcer
Therapeutics
Chemoprevention
Biomarkers
Colitis
Pharmaceutical Preparations
Tissue
Incidence
Enzymes

Keywords

  • Cancer
  • Carcinogenesis
  • Dihydroxyeicosatrienoic acids (DHETs)
  • Epoxyeicosatrienoic acids (EETs)
  • Inflammation
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Soluble epoxide hydrolase (sEH)
  • Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Epoxyeicosatrienoic acids and soluble epoxide hydrolase : Potential therapeutic targets for inflammation and its induced carcinogenesis. / Norwood, Stephanie; Liao, Jie; Hammock, Bruce D.; Yang, Guang Yu.

In: American Journal of Translational Research, Vol. 2, No. 4, 2010, p. 447-457.

Research output: Contribution to journalArticle

@article{495a7d2ba31043eba5eb24544f3791a9,
title = "Epoxyeicosatrienoic acids and soluble epoxide hydrolase: Potential therapeutic targets for inflammation and its induced carcinogenesis",
abstract = "Chronic inflammation is an important factor contributing to human carcinoma, and non-steroidal antiinflammatory drugs (NSAIDs) have been shown to have a preventive effect in the development of various types of carcinoma. However, NSAIDs also have adverse side effects including increased cardiovascular events, making them less than ideal for routine chemoprevention. Soluble epoxide hydrolase (sEH) is an enzyme that converts endogenous anti-inflammatory compounds, the epoxyeicosatrienoic acids (EETs), to the less anti-inflammatory dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH, by a highly selective and potent sEH inhibitor (sEHI), increases EETs leading to decreased inflammation. In our studies, administration of a sEHI in mouse colitis models led to decreased ulcer incidence and number of ulcers compared to controls, with no adverse side effects seen. In human tissue, sEH showed an increase in expression, as seen immunohistochemically, in ulcerative colitis (UC), UC-induced dysplasia, and UCinduced carcinoma. Thus, inhibition of sEH may be a novel biomarker and potential therapeutic target in inflammation and inflammation-induced carcinoma.",
keywords = "Cancer, Carcinogenesis, Dihydroxyeicosatrienoic acids (DHETs), Epoxyeicosatrienoic acids (EETs), Inflammation, Non-steroidal anti-inflammatory drugs (NSAIDs), Soluble epoxide hydrolase (sEH), Therapy",
author = "Stephanie Norwood and Jie Liao and Hammock, {Bruce D.} and Yang, {Guang Yu}",
year = "2010",
language = "English (US)",
volume = "2",
pages = "447--457",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "4",

}

TY - JOUR

T1 - Epoxyeicosatrienoic acids and soluble epoxide hydrolase

T2 - Potential therapeutic targets for inflammation and its induced carcinogenesis

AU - Norwood, Stephanie

AU - Liao, Jie

AU - Hammock, Bruce D.

AU - Yang, Guang Yu

PY - 2010

Y1 - 2010

N2 - Chronic inflammation is an important factor contributing to human carcinoma, and non-steroidal antiinflammatory drugs (NSAIDs) have been shown to have a preventive effect in the development of various types of carcinoma. However, NSAIDs also have adverse side effects including increased cardiovascular events, making them less than ideal for routine chemoprevention. Soluble epoxide hydrolase (sEH) is an enzyme that converts endogenous anti-inflammatory compounds, the epoxyeicosatrienoic acids (EETs), to the less anti-inflammatory dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH, by a highly selective and potent sEH inhibitor (sEHI), increases EETs leading to decreased inflammation. In our studies, administration of a sEHI in mouse colitis models led to decreased ulcer incidence and number of ulcers compared to controls, with no adverse side effects seen. In human tissue, sEH showed an increase in expression, as seen immunohistochemically, in ulcerative colitis (UC), UC-induced dysplasia, and UCinduced carcinoma. Thus, inhibition of sEH may be a novel biomarker and potential therapeutic target in inflammation and inflammation-induced carcinoma.

AB - Chronic inflammation is an important factor contributing to human carcinoma, and non-steroidal antiinflammatory drugs (NSAIDs) have been shown to have a preventive effect in the development of various types of carcinoma. However, NSAIDs also have adverse side effects including increased cardiovascular events, making them less than ideal for routine chemoprevention. Soluble epoxide hydrolase (sEH) is an enzyme that converts endogenous anti-inflammatory compounds, the epoxyeicosatrienoic acids (EETs), to the less anti-inflammatory dihydroxyeicosatrienoic acids (DHETs). Inhibition of sEH, by a highly selective and potent sEH inhibitor (sEHI), increases EETs leading to decreased inflammation. In our studies, administration of a sEHI in mouse colitis models led to decreased ulcer incidence and number of ulcers compared to controls, with no adverse side effects seen. In human tissue, sEH showed an increase in expression, as seen immunohistochemically, in ulcerative colitis (UC), UC-induced dysplasia, and UCinduced carcinoma. Thus, inhibition of sEH may be a novel biomarker and potential therapeutic target in inflammation and inflammation-induced carcinoma.

KW - Cancer

KW - Carcinogenesis

KW - Dihydroxyeicosatrienoic acids (DHETs)

KW - Epoxyeicosatrienoic acids (EETs)

KW - Inflammation

KW - Non-steroidal anti-inflammatory drugs (NSAIDs)

KW - Soluble epoxide hydrolase (sEH)

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77957374067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957374067&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 447

EP - 457

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 4

ER -